Streetbeat News

Earnings

SUPN

Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 earnings with an EPS of $0.39, missing estimates by -29% and a revenue decrease of $3.01 million from the previous year. Despite missing last quarter's EPS estimate, the share price increased by 11% the following day. The company's past earnings performance shows mixed results with both misses and beats on EPS and revenue estimates.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

KURA

Kura Oncology (NASDAQ:KURA) reported its Q4 earnings on February 27, 2024, with an EPS of $-0.55, matching the estimated earnings. The revenue remained unchanged from the same period last year. In the previous quarter, KURA beat the EPS estimate by $0.05, leading to a 7% increase in its share price the following day.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

FLYW

Flywire (NASDAQ:FLYW) reported Q4 earnings with an EPS of $0.01, surpassing the estimated -$0.07 by 114%. Revenue increased by $27.49 million year-over-year. Despite missing EPS estimates last quarter leading to a 25% share price drop, this quarter's performance marks a significant improvement.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

OSUR

OraSure Technologies (NASDAQ:OSUR) reported Q4 earnings with an EPS of $0.22, beating estimates by 175% but with a revenue decrease of $47.20 million from the previous year. The company has a history of surpassing EPS estimates, leading to share price increases.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

PRCT

PROCEPT BioRobotics (NASDAQ:PRCT) reported Q4 earnings with a -23.0% miss on estimated EPS, recording -$0.54 versus the -$0.44 estimate. Revenue increased by $19.80 million year-over-year. Despite the miss, past performance shows a positive trend in share price following earnings reports.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

SUPN

Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 2023 adjusted EPS of $0.39, missing the $0.55 estimate, but sales of $164.31M exceeded the $155.03M estimate, a 1.80% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:30 pm

DVN

Devon Energy reported its Q4 adjusted earnings per share (EPS) at $1.41, which was in line with expectations.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:29 pm

BYND

Beyond Meat Inc (NASDAQ:BYND) reported its Q4 financial results with a revenue of $73.7 million, surpassing estimates but experiencing a 7.8% decrease year-over-year. The company's EPS missed analyst expectations, reporting a loss of $2.40 per share. Beyond Meat's net loss was impacted by non-cash charges related to its global operations review. The company is focusing on resetting its business for sustainable operations and profitable growth, with a 2024 revenue forecast between $315 million and $345 million. Shares surged 37.1% after hours.

Portfolio Pulse from Adam Eckert

February 27, 2024 | 9:28 pm

PRCT

PROCEPT BioRobotics (NASDAQ:PRCT) reported Q4 2023 earnings with a GAAP EPS of $(0.54), missing the $(0.44) estimate, but sales of $43.58M exceeded the $42.06M forecast. This represents a 14.29% decrease in losses and an 83.29% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:28 pm

OSUR

OraSure Technologies (NASDAQ:OSUR) reported Q4 2023 adjusted EPS of $0.22, surpassing the $0.09 estimate, with sales of $75.88M exceeding the $74.12M estimate. This represents a 38.35% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:26 pm